Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Scientists investigate how diabetes drug boosts heart energy

NCT ID NCT05057806

First seen Apr 24, 2026 · Last updated Apr 29, 2026 · Updated 2 times

Summary

This early-phase study looks at how a common diabetes drug (SGLT2 inhibitor) changes the way the heart and muscles use ketones for energy. Researchers will measure energy levels, exercise capacity, and walking distance in 30 adults with type 2 diabetes and heart failure. The goal is to understand the drug's heart benefits, not to test a new treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH PRESERVED EJECTION FRACTION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Texas Health Science Center at San Antonio

    RECRUITING

    San Antonio, Texas, 78229, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.